RCUS

Arcus Biosciences, Inc.

RCUS · CIK 1724521 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$247M
20182025
Net Income−$353M
20182025
Operating CF−$482M
20182025
Free Cash Flow−$484M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.2B$0.3B$0.1B$0.1B$0.4B$0.0B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.5B$0.4B$0.3B$0.3B$0.3B$0.2B$0.1B$0.0B
SG&A Expense————————
Operating Income$-0.4B$-0.3B$-0.3B$-0.3B$0.1B$-0.1B$-0.1B$-0.1B
Net Income$-0.4B$-0.3B$-0.3B$-0.3B$0.1B$-0.1B$-0.0B$-0.0B
EPS (Basic)$-3.29$-3.14$-4.15$-3.71$0.76———
EPS (Diluted)$-3.29$-3.14$-4.15$-3.71$0.71———

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$1.1B$1.1B$1.1B$1.3B$1.6B$0.8B$0.2B$0.3B
Current Assets$1.0B$1.0B$0.8B$1.1B$1.3B$0.7B$0.2B$0.3B
Cash & Equivalents$0.2B$0.1B$0.1B$0.2B$0.1B$0.2B$0.1B$0.1B
Total Liabilities————$0.8B$0.3B$0.0B$0.0B
Current Liabilities$0.2B$0.2B$0.2B$0.2B$0.2B$0.1B$0.0B$0.0B
Stockholders' Equity$0.6B$0.5B$0.5B$0.7B$0.8B$0.5B$0.2B$0.2B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.5B$-0.2B$-0.3B$0.4B$-0.3B$0.1B$-0.1B$-0.0B
Investing Cash Flow$0.1B$-0.1B$0.2B$-0.4B$-0.0B$-0.4B$0.1B$-0.1B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.5B$0.3B$0.0B$0.0B$0.2B$0.4B$0.0B$0.1B
← Companies